07/25/2019
|
|
Taclonex Topical Suspension
|
|
calcipotriene and betamethasone dipropionate
|
|
Plaque psoriasis of the scalp and body in patients 12 years and older
|
|
*Safety and effectiveness for the treatment of plaque psoriasis of the scalp and body have been established in pediatric patients age 12 to 17 years. *Use for this indication is supported by evidence from adequate and well-controlled trials in adults and from three uncontrolled trials in 216 adolescents. *After 4 weeks of once daily treatment, HPA axis suppression was observed in 3% of adolescents with psoriasis of the scalp and 16% of adolescents with psoriasis of the scalp and body. *Safety and effectiveness in pediatric patients less than 12 years have not been established. *Information on safety, adverse reactions, and pharmacodynamics. *Postmarketing study.
|
|
P
|
|
LEO Pharm A/S
|
|
FALSE
|
|
Anti-inflammatory, topical
|
|